← Back

Pharma & biotech

16 covered stocks · 9 with direct model links · 12 with model news links

FBRXForte Biosciences76.99 0.00%
1 direct
▼FBRX 8-K — Completion of Acquisition or Disposition of Assets · Notice of Delisting or Failure to Satisfy a Listing Rule · Departure or Election of Directors or Officers
PFEPfizer28.69 -0.50%
2 direct1 2nd-order
▲Q3 Earnings & JOLTS Report on Midterm Voting Day
LLYEli Lilly1439.8 +1.00%
1 direct1 2nd-order
▲UBS portfolio manager: S&P 500 could hit 9,500 by June 2027 on AI, longevity, energy boom
NVONovo Nordisk40.95 +0.74%
2 direct
▲UBS portfolio manager: S&P 500 could hit 9,500 by June 2027 on AI, longevity, energy boom
AZNAstraZeneca185.38 +0.54%
1 direct1 2nd-order
▲AstraZeneca Partners With Oracle to Refine Clinical Research With AI
BIIBBiogen250.55 +0.03%
1 direct
▲Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
ZTSZoetis82.66 -0.37%
1 direct
▼Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
ABBVAbbVie294.5 +0.02%
1 direct
▲Dividend Announcements: October 24-30, 2026 (Part 1 Of 2)
JNJJohnson & Johnson286.77 +1.14%
1 direct
▲RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
REGNRegeneron954.19 +0.32%
1 2nd-order
▼REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
MRKMerck146.28 -0.46%
1 2nd-order
▲Q3 Earnings & JOLTS Report on Midterm Voting Day
AMGNAmgen465.18 -0.40%
1 2nd-order
▼Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform
BMYBristol Myers Squibb62.56 +0.38%
—
—
GILDGilead168.35 +0.24%
—
—
MRNAModerna227.82 -1.53%
—
—
VRTXVertex Pharmaceuticals538.33 -0.79%
—
—

Stock	Delayed quote	Model news links	Top-ranked story (model)
FBRX Forte Biosciences	76.99 0.00%	1 direct	▼FBRX 8-K — Completion of Acquisition or Disposition of Assets · Notice of Delisting or Failure to Satisfy a Listing Rule · Departure or Election of Directors or Officers
PFE Pfizer	28.69 -0.50%	2 direct1 2nd-order	▲Q3 Earnings & JOLTS Report on Midterm Voting Day
LLY Eli Lilly	1439.8 +1.00%	1 direct1 2nd-order	▲UBS portfolio manager: S&P 500 could hit 9,500 by June 2027 on AI, longevity, energy boom
NVO Novo Nordisk	40.95 +0.74%	2 direct	▲UBS portfolio manager: S&P 500 could hit 9,500 by June 2027 on AI, longevity, energy boom
AZN AstraZeneca	185.38 +0.54%	1 direct1 2nd-order	▲AstraZeneca Partners With Oracle to Refine Clinical Research With AI
BIIB Biogen	250.55 +0.03%	1 direct	▲Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
ZTS Zoetis	82.66 -0.37%	1 direct	▼Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
ABBV AbbVie	294.5 +0.02%	1 direct	▲Dividend Announcements: October 24-30, 2026 (Part 1 Of 2)
JNJ Johnson & Johnson	286.77 +1.14%	1 direct	▲RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
REGN Regeneron	954.19 +0.32%	1 2nd-order	▼REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
MRK Merck	146.28 -0.46%	1 2nd-order	▲Q3 Earnings & JOLTS Report on Midterm Voting Day
AMGN Amgen	465.18 -0.40%	1 2nd-order	▼Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform
BMY Bristol Myers Squibb	62.56 +0.38%	—	—
GILD Gilead	168.35 +0.24%	—	—
MRNA Moderna	227.82 -1.53%	—	—
VRTX Vertex Pharmaceuticals	538.33 -0.79%	—	—

Quotes are delayed. News links are model classifications, not verified article mentions; older records without a link type are grouped as direct. Ranking uses time-decayed model scores and preset analysis windows, not observed price effects or expected returns. A window ending does not establish that the market impact has ended.

← All industries